For the Quarter Ending March 2025
North America
In the first quarter of 2025, the Melatonin market in North America recorded a quarterly price rise of around 1.55% from previous quarter. This increase was supported by active procurement from melatonin supplement manufacturers and distributors. The seasonal transition from winter to spring played a part in keeping demand firm as consumers remained focused on sleep support and general wellness. The pharmaceutical and nutraceutical sectors showed steady offtake, especially as buyers moved to maintain well-planned inventories ahead of warmer months.
Melatonin suppliers in the region also benefited from smooth logistics and favourable supply conditions. Some influence came from ongoing tariff structures that encouraged local purchasing activity and kept buying interest stable for most of the quarter. Melatonin distributors adjusted their procurement cycles smartly to secure stock while avoiding overbuild, which kept supply-demand balanced.
Overall, the North American Melatonin market displayed healthy activity in first quarter of 2025 which was backed by solid downstream demand, good inventory management and supportive seasonal factors. The market sentiment stayed positive with suppliers reporting regular inquiries and moderate price adjustments.
Asia Pacific
In Asia Pacific, the Melatonin market experienced a modest average price increase of 0.10% during the first quarter of 2025. This trend was largely shaped by steady procurement activities from melatonin supplement and nutraceutical producers in the region. The Lunar New Year holidays in February resulted in temporarily slowed operations. This market temporary production slowdown was balanced by post-holiday restocking and helped in supporting the prices in upward direction.
Seasonal transition from winter to spring also contributed to sustained demand from downstream sectors such as pharmaceuticals and personal care. Melatonin suppliers in key exporting countries maintained reliable inventory positions and helped to ensure smooth distribution within the region. Although some downstream buyers showed cautious purchasing early in the quarter, but the strategic procurement activity picked up gradually as the quarter concluded.
Melatonin distributors responded to market signals and managed inventories effectively to match demand trends. Overall, the market remained balanced without sharp price fluctuations. The slight increase reflected healthy downstream consumption, supportive procurement strategies, and a steady pace of logistical operations across the Asia Pacific Melatonin market during Q1 2025.
Europe
The European Melatonin market in the first quarter of 2025 maintained a steady and controlled pricing pattern and broadly reflected the global market movements. Although pricing levels displayed minor variations across sources, the overall market sentiment held cautiously firm. Price levels demonstrated general stability with a modest upward inclination. This was supported by consistent demand from the pharmaceutical and nutraceutical sectors where melatonin supplements continued to gain consumer interest for sleep health and general wellness.
Melatonin suppliers in Europe reported regular inquiries and maintained strategic procurement schedules to prevent supply tightness. Distributors displayed careful inventory planning which helped in keeping market activity well balanced. Seasonal transition from colder months to early spring influenced purchasing patterns with steady buying observed throughout. The mild rise in demand was mainly driven by preparation for upcoming production cycles and positive downstream sentiment. The overall European Melatonin market in first quarter of 2025 remained steady. The moderate activity from both buyers and suppliers was reflected in a balanced supply-demand fundamentals and smooth distribution conditions.
For the Quarter Ending December 2024
North America
During quarter 4 of 2024, Melatonin prices in North America, especially in the US demonstrated a price increase of around 3.2% across the quarter. Values rose from $82080 per MT in October to $84700 per MT FOB New York in December 2024, displaying positive momentum. Price trends were driven by consistent purchasing activity from pharmaceutical and nutraceutical sectors, coupled with regular new customer inquiries throughout Q4.
Port infrastructure improvements and better logistics further supported price appreciation across the US. Market participants maintained high TEU volumes, with December bringing additional momentum as domestic suppliers implemented strategic pricing before the Christmas holiday. Export prices strengthened in the US market given the high offtake.
The market followed robust seasonal trends as 2024 concluded. Sustained end-user demand continued throughout the quarter, especially in pharmaceutical applications. This combination created an environment where supply chain stabilization and rising demand drove prices higher.
APAC
In Q4 2024, Melatonin prices in the Chinese domestic market demonstrated a consistent downward trend, declining from $73850 per MT in October to $72950 per MT FOB Shanghai by December 2024. The quarter began with Chinese Golden Week in October, which temporarily paused market activities, though international buyers maintained supply chain stability through advance procurement despite the production halt.
The downward momentum continued into November despite some resistance from China's nutraceutical sector, particularly from Western market demand. While lower freight rates provided some cost relief to manufacturers through improved logistics efficiency, this wasn't enough to reverse the overall declining price trajectory.
December saw further price softening as manufacturers implemented destocking initiatives ahead of the holiday season. Although demand remained stable across domestic and international channels, the continued inventory optimization efforts by producers sustained the downward pressure on prices. This persistent decline throughout the quarter created favorable buying conditions, even as fundamental demand stayed resilient.
Europe
Germany's Melatonin market in Q4 2024 experienced several notable fluctuations influenced by supply-demand dynamics and strategic inventory management. The quarter commenced with an upward price trajectory, driven by intensifying demand patterns and ongoing logistics disruptions affecting timely deliveries. By early November, the market witnessed heightened pressure as end-user demand stayed high while supply remained constrained. This imbalance created favorable conditions for sellers, who capitalized by implementing strategic price increases and enjoying improved profit margins.
Mid-November saw further tightening of supply chains, particularly affecting European distribution networks. However, the market dynamics shifted significantly in December as major European distributors initiated systematic inventory reduction programs. This strategic move created opportunities for buyers, leading to increased sourcing from Asian manufacturers who offered competitive pre-holiday rates. Despite these procurement shifts, the underlying pharmaceutical sector consumption remained remarkably stable.
The quarter concluded with a moderation in prices, primarily attributed to strategic inventory management decisions rather than any fundamental weakening in demand patterns. Industrial consumers, particularly in the pharmaceutical sector, maintained steady consumption levels throughout the period. Asian suppliers gained market share during this period, capitalizing on European inventory reduction initiatives.
For the Quarter Ending September 2024
North America
The Melatonin market in North America showcased moderate stability during Q3 2024, with the United States retaining its status as the primary trading hub. Price levels followed a gradual downward trajectory, declining from $86000/MT to $81960/MT FOB New York from July to September 2024. This quarter's softening prices contrasted with the previous quarter's continued depreciation, as market gained momentum in the later in the quarter. The modest price depreciation reflected subtle shifts in industry dynamics amid steady broader economic indicators.
Despite the slight price erosion, consumption patterns from domestic nutraceutical and pharmaceutical industries remained dependable, while efficient logistics management helped maintain supply-side balance. The market demonstrated resilience amid persistent operational challenges, including maritime congestion, shipping costs, and distribution network intricacies. The gentle price decline was partially influenced by competitive pricing in China's market, a key Melatonin supplier, creating a ripple effect across the American nutraceutical sector.
The measured price depreciation, occurring gradually across the quarter, indicates evolving market fundamentals while maintaining underlying stability. This trend aligns with broader regional patterns, showcasing the North American Melatonin market's ability to adapt despite ongoing supply chain complexities. The delicate balance between regional demand, global supply dynamics, and logistical factors has fostered a nuanced yet stable pricing environment.
APAC
The Melatonin market in Asia-Pacific displayed a slight downward pricing trend in Q3 2024, characterized by measured market adjustments. China's market experienced modest price softening quarter-over-quarter, while maintaining its position as the regional price benchmark. The market witnessed a gentle decline in price levels, with export values easing from $77700/MT to $73025/MT FOB Shanghai between July and September 2024.
This controlled price depreciation reflected well-managed operational factors and steady market fundamentals. Demand patterns maintained consistent procurement from nutraceutical and pharmaceutical industries, both domestic and international, while supply elements remained abundant despite ongoing production costs and operational considerations. The interaction between production capacity and logistical frameworks facilitated a controlled market adjustment throughout the quarter.
Market stability, despite the price softening, was evident through steady buyer engagement and predictable order patterns. These consistent demand indicators, combined with efficient operational management including freight expenses and supply chain processes, allowed industry participants to maintain workable margins. China's domestic market continued to guide regional price trends, balancing international procurement patterns with domestic consumption dynamics. The coordination between production capabilities and logistical frameworks supported a controlled market adjustment.
Europe
The European Melatonin landscape experienced a gentle price decline mimicking the Asian markets during Q3 2024, with Germany's market dynamics serving as the key regional indicator. The quarterly performance showed consistent but slightly decreasing price levels between the first and second half, maintaining overall market balance. Despite historical volatility, the market demonstrated controlled adjustment with steady quarterly performance.
The measured price depreciation stemmed from well-managed supply capabilities and steady demand patterns amid high inventory levels. Manufacturing processes, particularly in Asian production centers, maintained optimal output levels influencing the gradual price adjustment in Germany. This was supported by reliable demand from pharmaceutical and nutraceutical sectors maintaining predictable procurement activities.
Germany's market trends continued to provide a benchmark for European pricing patterns, exhibiting consistent seasonal performance despite the modest price softening. Through operational challenges, the market maintained its fundamental equilibrium, underlining the European Melatonin market's inherent stability. The balance between supply capabilities, sectoral demand patterns, and regional market forces fostered a slightly declining but stable pricing environment, characterized by measured adjustment and market equilibrium across Europe.
For the Quarter Ending June 2024
North America
The second quarter of 2024 has been marked by a notable decline in Melatonin prices across the North American region, driven by several intricate market dynamics. Supply chain disruptions and a decrease in demand from key sectors such as pharmaceuticals and nutraceuticals have played significant roles in this downward trend. Additionally, a surplus of inventory and increased price competition from Asian producers have further exerted pressure on prices.
In the USA, which has experienced the most substantial price fluctuations, the overall trend has been consistently negative. Seasonal factors and the interplay of supply and demand have resulted in a complex pricing environment. Compared to the same quarter last year, Melatonin prices have plummeted by 20%, reflecting a stark contrast with the previous quarter of 2024, which saw an 8% decrease.
The quarter-ending price settled at USD 90,000 per metric ton of Melatonin FOB New York, underscoring the ongoing depressive sentiment in the market. The pricing environment has been predominantly negative, influenced by abundant supply, diminishing demand, and import challenges. Overall, the second quarter of 2024 has underscored a challenging landscape for Melatonin prices in North America, particularly in the USA, with a consistent downward trajectory driven by multifaceted market factors.
Asia Pacific
The second quarter of 2024 has witnessed a notable decline in Melatonin prices across the APAC region, driven by several critical factors. Market oversupply, coupled with subdued demand from both domestic and international end-users, has exerted downward pressure on prices. The Red Sea crisis has exacerbated shipping costs, disrupting purchasing strategies and intensifying cautious market sentiment. Consequently, producers have been compelled to lower prices to manage their inventories effectively. The increased production amidst declining demand has deepened the oversupply scenario, further pushing prices down.
Focusing on China, the region that experienced the most significant price changes, the overall trend in Melatonin pricing has been distinctly negative. Seasonality and fluctuating international demand have played pivotal roles in shaping this trend. From the previous quarter in 2024, prices saw a modest decrease of 1%, reflecting the sustained bearish market sentiment. A comparison between the first and second halves of the quarter reveals a further price reduction of 3%, underscoring the persistent downward trajectory. The quarter ended with Melatonin priced at USD 80,000 per metric ton FOB Qingdao, highlighting the ongoing deflationary pressure.
In summary, the pricing environment for Melatonin in the APAC region during Q2 2024 has been predominantly negative, influenced by an oversupply situation, increased logistical costs, and tepid demand. The confluence of these factors has resulted in a consistent decline in prices, with China seeing the most pronounced impact.
Europe
The Melatonin market in Europe largely mirrored the dynamics of the Chinese domestic market in Q2 2024, experiencing a notable downtrend driven by several critical factors. The quarter was characterized by a confluence of declining demand from key sectors such as nutraceuticals and pharmaceuticals, coupled with hampered supply chain conditions. The availability of Melatonin stockpiles, especially from major Asian exporters, led to competitive pricing pressures. Additionally, the easing of global trade disruptions and reduced freight costs this quarter contributed to the downward price adjustments. Economic factors, including a slight recovery in inflation and improved consumer confidence, partially offset the downward momentum but were not sufficient to reverse the overall trend.
Germany, the epicenter of the price volatility, saw a significant shift in its Melatonin market. Seasonal factors, such as reduced consumption during warmer months and ample inventory levels, exacerbated the price decrease. The pricing environment in Q2 2024 reflected a predominantly negative sentiment, driven by an overabundance of supply and stabilizing trade conditions, overshadowing any minor demand recovery.
This downturn was further influenced by the easing of supply chain bottlenecks that had previously constrained the market. As logistics improved and production capabilities expanded, the increased availability of Melatonin intensified competition among suppliers. The quarter also saw shifts in consumer behavior, with changing preferences and potentially reduced usage of sleep aids during the spring and early summer months contributing to the softer demand.
The market dynamics observed during this period had varying impacts across the industry. While challenging for Melatonin suppliers, the lower prices potentially benefited consumers and downstream industries relying on Melatonin as an input. However, the prolonged price pressure raised questions about its long-term impact on research and development investments in the Melatonin sector.
Overall, Q2 2024 marked a period of significant adjustment in the European Melatonin market, with the interplay of supply, demand, and broader economic factors resulting in a notably bearish quarter for the industry.
